bupropion has been researched along with Pregnancy in 107 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
Excerpt | Relevance | Reference |
---|---|---|
"There were no significant differences in the safety measures across the treatment arms and bupropion was not efficacious in promoting smoking cessation at the end of treatment (7-day point prevalence quit rates: bupropion, 11." | 9.41 | Placebo-controlled trial of bupropion for smoking cessation in pregnant women. ( Hand, DJ; Hoffman, M; Kranzler, HR; Oncken, C; Schnoll, RA; Srinivas, S; Washio, Y; Wileyto, EP; Zindel, LR, 2021) |
"We searched MEDLINE, EMBASE, CINAHL, and PsychINFO databases for studies of any design reporting pregnancy outcomes after bupropion or varenicline exposure." | 9.01 | Systematic Review and Meta-Analysis to Assess the Safety of Bupropion and Varenicline in Pregnancy. ( Coleman, T; Jones, M; Turner, E; Vaz, LR, 2019) |
"While more studies are needed, research to date suggests that bupropion may be a reasonable treatment option for depressed pregnant women who require pharmacotherapy, particularly when they also are attempting to reduce nicotine use during pregnancy." | 8.95 | Bupropion Use During Pregnancy: A Systematic Review. ( Gitlin, MJ; Hendrick, V; Ortiz-Portillo, E; Suri, R, 2017) |
"Nicotine addiction has been identified as the primary contributor to continued widespread tobacco use worldwide." | 8.81 | Managing nicotine addiction. ( Hatsukami, DK; Kotlyar, M, 2002) |
"Bupropion is used for treatment of depression during pregnancy." | 7.83 | Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid. ( Ahmed, MS; Clark, SM; Fokina, VM; Hankins, GD; Nanovskaya, TN; Oncken, C; West, H, 2016) |
"Fetal and neonatal exposure to the smoking cessation drug bupropion, unlike NRT, does not appear to adversely affect metabolic outcomes or the fertility of the female offspring." | 7.79 | Postnatal metabolic and reproductive consequences of fetal and neonatal exposure to the smoking cessation drug bupropion. ( De Long, N; Gerstein, HC; Holloway, AC; Hyslop, JR; Morrison, KM; Nicholson, CJ, 2013) |
" The mother had received bupropion, an antidepressant and aid to smoking cessation, throughout pregnancy." | 7.77 | Hyperinsulinism associated with gestational exposure to bupropion in a newborn infant. ( Gisslen, T; Nathan, B; Rao, R; Thompson, T, 2011) |
"Reports from the GlaxoSmithKline Bupropion Pregnancy Registry suggested an increase in cardiovascular defects following exposure to bupropion during pregnancy." | 7.74 | Bupropion in pregnancy and the prevalence of congenital malformations. ( Cole, JA; Cosmatos, IS; Haight, BR; Modell, JG; Stoler, JM; Walker, AM, 2007) |
"Bupropion was developed for the treatment of depression, but subsequently was found to be effective for smoking cessation." | 7.73 | Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. ( Boshier, A; Chun-Fai-Chan, B; Einarson, A; Fayez, I; Kalra, S; Koren, G; Shakir, S; Voyer-Lavigne, S, 2005) |
"Bupropion (Zyban) is the first new pharmacological treatment for smoking cessation to be introduced since nicotine replacement therapy." | 7.72 | Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. ( Boshier, A; Shakir, SA; Wilton, LV, 2003) |
"Treatment with nicotine replacement therapy or bupropion doubles the one-year success rate after cessation of smoking." | 6.41 | [Treatment of nicotine addiction. Drug therapy for smoking cessation]. ( Christensen, HR; Døssing, M; Pedersen, ST, 2002) |
" Paired t tests were used to compare pharmacokinetic parameters during pregnancy and postpartum." | 5.62 | Pregnancy Has No Clinically Significant Effect on the Pharmacokinetics of Bupropion or Its Metabolites. ( Czuba, LC; Fay, EE; Isoherranen, N; Sager, JE; Shum, S; Stephenson-Famy, A, 2021) |
"There were no significant differences in the safety measures across the treatment arms and bupropion was not efficacious in promoting smoking cessation at the end of treatment (7-day point prevalence quit rates: bupropion, 11." | 5.41 | Placebo-controlled trial of bupropion for smoking cessation in pregnant women. ( Hand, DJ; Hoffman, M; Kranzler, HR; Oncken, C; Schnoll, RA; Srinivas, S; Washio, Y; Wileyto, EP; Zindel, LR, 2021) |
"We included randomised controlled trials (RCTs), cluster-RCTs and factorial RCTs, which measured smoking cessation at six months or longer, recruited adults who smoked combustible cigarettes at enrolment (excluding pregnant people) and randomised them to approved pharmacotherapies and technologies used for smoking cessation worldwide (varenicline, cytisine, nortriptyline, bupropion, nicotine replacement therapy (NRT) and e-cigarettes) versus no pharmacological intervention, placebo (control) or another approved pharmacotherapy." | 5.41 | Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. ( Agrawal, S; Aveyard, P; Fanshawe, TR; Freeman, SC; Hajizadeh, A; Hartmann-Boyce, J; Lindson, N; Livingstone-Banks, J; Ordóñez-Mena, JM; Sutton, AJ; Theodoulou, A; Zhu, S, 2023) |
"(3) An increased risk of birth defects, particularly cardiac malformations, is also suspected after exposure to amphetamine derivatives during pregnancy." | 5.33 | Bupropion (amfebutamone): caution during pregnancy. ( , 2005) |
"Individual smoking cessation counseling along with the twice-daily use of 150 mg bupropion sustained release increased smoking cessation rates and reduced cravings and total nicotine withdrawal symptoms during the treatment period." | 5.24 | Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial. ( Ahmed, MS; Clark, SM; Feinn, RS; Fokina, VM; Hankins, GDV; Jain, SK; Nanovskaya, TN; Oncken, C; West, H, 2017) |
"This initial attempt to evaluate bupropion for smoking cessation during pregnancy will inform future trial methodology." | 5.20 | Randomized, controlled pilot trial of bupropion for pregnant smokers: challenges and future directions. ( Blackwell, S; Blalock, JA; Cinciripini, PM; Minnix, JA; Mullen, PD; Northrup, TF; Pedroza, C; Stotts, AL, 2015) |
"Bupropion's efficacy for smoking cessation in pregnant women is unknown." | 5.14 | The relationship between antidepressant use and smoking cessation in pregnant women in treatment for substance abuse. ( Brigham, EP; Chisolm, MS; Jones, HE; Strain, EC; Tuten, M, 2010) |
" When used by non-pregnant smokers, pharmacotherapies (nicotine replacement therapy (NRT), bupropion, and varenicline) are effective for increasing smoking cessation, however their efficacy and safety in pregnancy remains unknown." | 5.05 | Pharmacological interventions for promoting smoking cessation during pregnancy. ( Berlin, I; Chamberlain, C; Claire, R; Coleman, T; Cooper, SE; Davey, MA; Leonardi-Bee, J, 2020) |
"We searched MEDLINE, EMBASE, CINAHL, and PsychINFO databases for studies of any design reporting pregnancy outcomes after bupropion or varenicline exposure." | 5.01 | Systematic Review and Meta-Analysis to Assess the Safety of Bupropion and Varenicline in Pregnancy. ( Coleman, T; Jones, M; Turner, E; Vaz, LR, 2019) |
"While more studies are needed, research to date suggests that bupropion may be a reasonable treatment option for depressed pregnant women who require pharmacotherapy, particularly when they also are attempting to reduce nicotine use during pregnancy." | 4.95 | Bupropion Use During Pregnancy: A Systematic Review. ( Gitlin, MJ; Hendrick, V; Ortiz-Portillo, E; Suri, R, 2017) |
" Nous avons mené des recherches dans les bases de données PubMed, Medline, EMBASE et Cochrane en vue d’en tirer les études pertinentes (1990-2014) au moyen des termes de recherche suivants : smoking cessation, pregnancy, medicine, behavioural, nicotine replacement products, bupropion et varenicline." | 4.91 | Smoking Cessation Strategies in Pregnancy. ( Davies, GA; Leung, LW, 2015) |
"To determine the efficacy and safety of smoking cessation pharmacotherapies (including NRT, varenicline and bupropion), other medications, or ENDS when used for smoking cessation in pregnancy." | 4.91 | Pharmacological interventions for promoting smoking cessation during pregnancy. ( Chamberlain, C; Coleman, T; Cooper, SE; Davey, MA; Leonardi-Bee, J, 2015) |
"Cochrane systematic review evidence from 2013 suggests that adding mood management to behavioural support may improve cessation outcomes in smokers with current or past depression and strengthens evidence for previous conclusions, including the safety of varenicline and bupropion and the benefits of behavioural support for smoking cessation in pregnancy." | 4.90 | Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. ( Cahill, K; Hartmann-Boyce, J; Lancaster, T; Stead, LF, 2014) |
"There are insufficient data at this time to recommend the use of varenicline and/or bupropion for smoking cessation during pregnancy." | 4.90 | Is it safe to use smoking cessation therapeutics during pregnancy? ( Barra, NG; De Long, NE; Hardy, DB; Holloway, AC, 2014) |
" To date, three medications are FDA-approved for smoking cessation: nicotine replacement therapy, sustained-release bupropion, and varenicline." | 4.87 | Pharmacotherapy for smoking cessation: present and future. ( Aubin, HJ; Karila, L; Reynaud, M, 2011) |
" This review article provides an overview of comprehensive (the 5 A's framework: Ask, Advise, Assess, Assist, Arrange) and brief (Ask, Advise, Refer) interventions for assisting patients with quitting, and a more detailed review of the seven first-line pharmacological agents for smoking cessation (nicotine replacement therapy formulations, bupropion SR and varenicline) and combination therapy regimens." | 4.86 | Current approaches to pharmacotherapy for smoking cessation. ( Corelli, RL; Hudmon, KS; Prokhorov, AV, 2010) |
" There are now eight effective pharmacotherapies (nicotine gum, patch, nasal spray, inhaler, lozenge/tablet, bupropion, nortriptyline and clonidine) available to aid smoking cessation." | 4.83 | Developments in pharmacotherapy for tobacco dependence: past, present and future. ( Foulds, J; Steinberg, MB; Williams, JM; Ziedonis, DM, 2006) |
"Nicotine addiction has been identified as the primary contributor to continued widespread tobacco use worldwide." | 4.81 | Managing nicotine addiction. ( Hatsukami, DK; Kotlyar, M, 2002) |
" All forms of nicotine replacement therapy (NRT) -- gum, patches and inhaler -- and bupropion are safe and effective for increasing smoking cessation rates in the short and long terms." | 4.81 | The pharmacotherapy of smoking cessation. ( Morgan, LC; Peters, MJ, 2002) |
" The general population model included age, hepatitis C virus infection, days of opioid used by type, number of cigarettes used daily, and the following medications used in the last 30 day of pregnancy: bupropion, antinausea medicines, benzodiazepines, antipsychotics, and gabapentin." | 4.02 | Development and Validation of a Model to Predict Neonatal Abstinence Syndrome. ( Cooper, WO; Dudley, J; Harrell, FE; Hartmann, K; Martin, PR; Patrick, SW; Slaughter, JC; Stratton, S, 2021) |
"Providers were more concerned about bupropion and varenicline than other medications within the same pregnancy risk categories." | 3.96 | Health-care providers' concern regarding smoking cessation pharmacotherapies during pregnancy: Calls to a teratology information service. ( Havard, A; Kennedy, D; Lee, ML; Tran, DT; Welsh, A, 2020) |
"Pregnant smokers recruited to participate in a placebo-controlled trial of bupropion for smoking cessation provided a blood sample for measurement of NMR." | 3.96 | Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study. ( Hand, D; Kranzler, HR; Lynch, KG; Oncken, C; Schnoll, R; Tyndale, RF; Washio, Y; Zindel, LR, 2020) |
"Bupropion (BUP) has a potential to be an effective pharmacotherapy for smoking cessation during pregnancy." | 3.85 | The Role of Placental Carbonyl Reducing Enzymes in Biotransformation of Bupropion and 4-methylnitrosamino-1-(3-pyridyl)-1-butanone. ( Ahmed, MS; Fokina, VM; Hankins, GDV; Nanovskaya, T; Oncken, C; Patrikeeva, SL, 2017) |
"Bupropion is used for treatment of depression during pregnancy." | 3.83 | Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid. ( Ahmed, MS; Clark, SM; Fokina, VM; Hankins, GD; Nanovskaya, TN; Oncken, C; West, H, 2016) |
"Bupropion and nicotine patch replacement therapy have an impact on smoking cessation during and after pregnancy." | 3.83 | Success of smoking cessation interventions during pregnancy. ( Bérard, A; Sheehy, O; Zhao, JP, 2016) |
"The use of antidepressant drug bupropion hydrochloride (BPN) during pregnancy results in increased cardiovascular anomalies." | 3.80 | Evaluation of bupropion hydrochloride developmental cardiotoxic effects in chick cardiomyocyte micromass culture and stem cell derived cardiomyocyte systems. ( Latif, ML; Parker, TL; Pratten, MK; Shaikh Qureshi, WM, 2014) |
" Exposure categories included first-trimester bupropion alone or in combination with other antidepressants, first-trimester antidepressants other than bupropion, and no exposure to any antidepressant at any time from 2 months prior to pregnancy through delivery." | 3.80 | First-trimester exposure to bupropion and risk of cardiac malformations. ( Kerr, S; Louik, C; Mitchell, AA, 2014) |
" This infant was reported to be free from typical perinatal risk factors of hyperinsulinism except for the fact that the mother of the baby was receiving the antidepressant bupropion during her pregnancy." | 3.79 | Bupropion can close KATP channel and induce insulin secretion. ( Dezaki, K; Galvanovskis, J; Iwasaki, Y; Maejima, Y; Nakata, M; Sakuma, K; Shimomura, K; Yada, T; Yang, Y, 2013) |
"Fetal and neonatal exposure to the smoking cessation drug bupropion, unlike NRT, does not appear to adversely affect metabolic outcomes or the fertility of the female offspring." | 3.79 | Postnatal metabolic and reproductive consequences of fetal and neonatal exposure to the smoking cessation drug bupropion. ( De Long, N; Gerstein, HC; Holloway, AC; Hyslop, JR; Morrison, KM; Nicholson, CJ, 2013) |
"Bupropion, an amphetamine, is authorised as an aid to smoking cessation, despite its negative harm-benefit balance." | 3.78 | Bupropion: congenital heart defects (continued). ( , 2012) |
" The mother had received bupropion, an antidepressant and aid to smoking cessation, throughout pregnancy." | 3.77 | Hyperinsulinism associated with gestational exposure to bupropion in a newborn infant. ( Gisslen, T; Nathan, B; Rao, R; Thompson, T, 2011) |
"In order to evaluate the potential use of bupropion as smoking cessation therapy during pregnancy, the aim of this investigation was to determine transplacental transfer and metabolism of bupropion and its distribution among placental tissue and maternal and fetal circuits of the dually perfused placental lobule." | 3.76 | Transplacental transfer and metabolism of bupropion. ( Abdelrahman, DR; Ahmed, MS; Earhart, AD; Hankins, GD; Nanovskaya, T; Patrikeeva, S; Wang, X, 2010) |
"We identified a positive association between early pregnancy bupropion use and left outflow tract heart defects; however, the magnitude of the observed increased risk was small." | 3.76 | Maternal use of bupropion and risk for congenital heart defects. ( Alwan, S; Botto, LD; Correa, A; Friedman, JM; Rasmussen, SA; Reefhuis, J, 2010) |
"Children of mothers treated with bupropion during pregnancy have an increased risk of being diagnosed with ADHD; a possible causal effect needs to be further studied." | 3.76 | Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. ( Figueroa, R, 2010) |
"Reports from the GlaxoSmithKline Bupropion Pregnancy Registry suggested an increase in cardiovascular defects following exposure to bupropion during pregnancy." | 3.74 | Bupropion in pregnancy and the prevalence of congenital malformations. ( Cole, JA; Cosmatos, IS; Haight, BR; Modell, JG; Stoler, JM; Walker, AM, 2007) |
"Bupropion was developed for the treatment of depression, but subsequently was found to be effective for smoking cessation." | 3.73 | Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. ( Boshier, A; Chun-Fai-Chan, B; Einarson, A; Fayez, I; Kalra, S; Koren, G; Shakir, S; Voyer-Lavigne, S, 2005) |
"Bupropion (Zyban) is the first new pharmacological treatment for smoking cessation to be introduced since nicotine replacement therapy." | 3.72 | Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. ( Boshier, A; Shakir, SA; Wilton, LV, 2003) |
"Smoking during pregnancy has detrimental effects on mother and fetus." | 2.87 | Smoking Cessation Following Text Message Intervention in Pregnant Women. ( Chamness, D; Forinash, AB; Gross, G; Inteso, C; Koerner, J; Mathews, K; Miller, C; Yancey, A, 2018) |
"Bupropion SR was well tolerated, and no subjects discontinued treatment as a result of medication side-effects." | 2.71 | Bupropion SR for the treatment of postpartum depression: a pilot study. ( Cohen, LS; Nonacs, RM; Pearson, K; Poitras, JR; Soares, CN; Viguera, AC, 2005) |
"Perinatal depression is associated with serious risks for the mother, baby, and family." | 2.58 | Pharmacotherapy for Perinatal Depression. ( Albertini, ES; Ernst, C; Fersh, ME; Habib, S; Khan, SJ; Lusskin, SI, 2018) |
" A few minor adverse effects and serious adverse effects were reported in several studies." | 2.48 | Efficacy and safety of pharmacotherapy for smoking cessation among pregnant smokers: a meta-analysis. ( Ju, W; Jung, HS; Kim, H; Myung, SK; Oh, SW; Park, CH; Seo, H, 2012) |
"Bupropion was effective at long-term follow-up (pooled OR 1." | 2.46 | A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. ( Agboola, S; Coleman, T; Leonardi Bee, J; McNeill, A, 2010) |
"Smoking during pregnancy is a significant public health concern." | 2.42 | Pharmacotherapies to enhance smoking cessation during pregnancy. ( Kranzler, HR; Oncken, CA, 2003) |
"Treatment with nicotine replacement therapy or bupropion doubles the one-year success rate after cessation of smoking." | 2.41 | [Treatment of nicotine addiction. Drug therapy for smoking cessation]. ( Christensen, HR; Døssing, M; Pedersen, ST, 2002) |
" Neonatal providers should be aware of maternal medications and prepare for possible adverse effects, particularly from common psychotropic exposures." | 1.62 | Why the Maternal Medication List Matters: Neonatal Toxicity From Combined Serotonergic Exposures. ( Brajcich, MR; Marks, J; Messer, RD; Murphy, ME; Palau, MA, 2021) |
"Varenicline may increase the risk of coronary events." | 1.38 | Promoting smoking cessation. ( Larzelere, MM; Williams, DE, 2012) |
"Bupropion was metabolized by baboon hepatic and placental microsomes to hydroxybupropion (OH-BUP), threo- (TB) and erythrohydrobupropion (EB)." | 1.37 | Metabolism of bupropion by baboon hepatic and placental microsomes. ( Abdelrahman, DR; Ahmed, MS; Fokina, VM; Hankins, GD; Nanovskaya, TN; Wang, X, 2011) |
"Bupropion was transported by BCRP (K(t) 3 microM, V(max) 30 pmol/mg protein/min) and P-gp (K(t) 0." | 1.36 | Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. ( Abdelrahman, DR; Ahmed, MS; Hankins, GD; Hemauer, SJ; Nanovskaya, TN; Patrikeeva, SL; Wang, X, 2010) |
"Smoking during pregnancy is the largest modifiable risk factor for pregnancy-related morbidity and mortality." | 1.36 | Bupropion metabolism by human placenta. ( Abdelrahman, DR; Ahmed, MS; Hankins, GD; Nanovskaya, TN; Patrikeeva, SL; Wang, X; Zharikova, OL, 2010) |
"(3) An increased risk of birth defects, particularly cardiac malformations, is also suspected after exposure to amphetamine derivatives during pregnancy." | 1.33 | Bupropion (amfebutamone): caution during pregnancy. ( , 2005) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (1.87) | 18.7374 |
1990's | 1 (0.93) | 18.2507 |
2000's | 32 (29.91) | 29.6817 |
2010's | 58 (54.21) | 24.3611 |
2020's | 14 (13.08) | 2.80 |
Authors | Studies |
---|---|
Marks, C | 1 |
Silvola, R | 1 |
Teal, E | 1 |
Quinney, SK | 1 |
Haas, DM | 1 |
Levander, XA | 1 |
Carmody, T | 1 |
Cook, RR | 1 |
Potter, JS | 1 |
Trivedi, MH | 1 |
Korthuis, PT | 1 |
Shoptaw, S | 1 |
Speck, ML | 1 |
Gomes, ALA | 1 |
Rojas, CS | 1 |
Willig, JB | 1 |
Herrmann, AP | 1 |
Pilger, DA | 1 |
Rates, SMK | 1 |
Rábade-Castedo, C | 1 |
de Granda-Orive, JI | 1 |
Riesco-Miranda, JA | 1 |
De Higes-Martínez, E | 1 |
Ramos-Pinedo, Á | 1 |
Cabrera-César, E | 1 |
Signes-Costa Miñana, J | 1 |
García Rueda, M | 1 |
Pastor-Esplá, E | 1 |
Jiménez-Ruiz, CA | 1 |
Lindson, N | 1 |
Theodoulou, A | 1 |
Ordóñez-Mena, JM | 1 |
Fanshawe, TR | 2 |
Sutton, AJ | 1 |
Livingstone-Banks, J | 3 |
Hajizadeh, A | 1 |
Zhu, S | 1 |
Aveyard, P | 2 |
Freeman, SC | 1 |
Agrawal, S | 1 |
Hartmann-Boyce, J | 5 |
Lee, ML | 1 |
Tran, DT | 1 |
Welsh, A | 1 |
Kennedy, D | 1 |
Havard, A | 1 |
Claire, R | 1 |
Chamberlain, C | 2 |
Davey, MA | 2 |
Cooper, SE | 2 |
Berlin, I | 2 |
Leonardi-Bee, J | 2 |
Coleman, T | 4 |
Kranzler, HR | 4 |
Washio, Y | 2 |
Zindel, LR | 2 |
Lynch, KG | 1 |
Hand, D | 1 |
Tyndale, RF | 1 |
Oncken, C | 7 |
Schnoll, R | 1 |
Anderson, KN | 1 |
Lind, JN | 1 |
Simeone, RM | 1 |
Bobo, WV | 1 |
Mitchell, AA | 2 |
Riehle-Colarusso, T | 1 |
Polen, KN | 1 |
Reefhuis, J | 3 |
Patrick, SW | 1 |
Slaughter, JC | 1 |
Harrell, FE | 1 |
Martin, PR | 1 |
Hartmann, K | 1 |
Dudley, J | 1 |
Stratton, S | 1 |
Cooper, WO | 1 |
Wileyto, EP | 1 |
Srinivas, S | 1 |
Hand, DJ | 1 |
Hoffman, M | 1 |
Schnoll, RA | 1 |
Brajcich, MR | 1 |
Palau, MA | 1 |
Messer, RD | 1 |
Murphy, ME | 1 |
Marks, J | 1 |
Fay, EE | 1 |
Czuba, LC | 1 |
Sager, JE | 1 |
Shum, S | 1 |
Stephenson-Famy, A | 1 |
Isoherranen, N | 2 |
Fan, T | 2 |
Lee, G | 1 |
Scheuermann, TS | 1 |
Richter, KP | 1 |
Jacobson, LT | 1 |
Shireman, TI | 1 |
Baraona, LK | 1 |
Lovelace, D | 1 |
Daniels, JL | 1 |
McDaniel, L | 1 |
Fokina, VM | 5 |
Patrikeeva, SL | 3 |
Hankins, GDV | 2 |
Ahmed, MS | 10 |
Nanovskaya, T | 2 |
Hendrick, V | 1 |
Suri, R | 1 |
Gitlin, MJ | 1 |
Ortiz-Portillo, E | 1 |
Lusskin, SI | 1 |
Khan, SJ | 1 |
Ernst, C | 1 |
Habib, S | 1 |
Fersh, ME | 1 |
Albertini, ES | 1 |
Turner, E | 1 |
Jones, M | 1 |
Vaz, LR | 1 |
Forinash, AB | 1 |
Yancey, A | 1 |
Chamness, D | 1 |
Koerner, J | 1 |
Inteso, C | 1 |
Miller, C | 1 |
Gross, G | 1 |
Mathews, K | 1 |
Barboza, J | 1 |
Norris, E | 1 |
West, R | 2 |
Jarvis, M | 1 |
Hajek, P | 1 |
Hong, B | 1 |
Wheat, H | 1 |
Sanches, ESAM | 1 |
Tsuzuki, F | 1 |
Joinhas, F | 1 |
Figueiras, GB | 1 |
Moreira, EG | 1 |
Salles, MJS | 1 |
De Long, N | 1 |
Hyslop, JR | 1 |
Nicholson, CJ | 1 |
Morrison, KM | 1 |
Gerstein, HC | 1 |
Holloway, AC | 2 |
Aubin, HJ | 2 |
Luquiens, A | 1 |
Trivedi, D | 1 |
Louik, C | 1 |
Kerr, S | 1 |
Freeman, MP | 1 |
Stead, LF | 1 |
Cahill, K | 1 |
Lancaster, T | 1 |
Rytting, E | 2 |
Wang, X | 6 |
Vernikovskaya, DI | 2 |
Zhan, Y | 1 |
Bauer, C | 1 |
Abdel-Rahman, SM | 1 |
Nanovskaya, TN | 9 |
Stotts, AL | 1 |
Northrup, TF | 1 |
Cinciripini, PM | 1 |
Minnix, JA | 1 |
Blalock, JA | 1 |
Mullen, PD | 1 |
Pedroza, C | 1 |
Blackwell, S | 1 |
Shaikh Qureshi, WM | 1 |
Latif, ML | 1 |
Parker, TL | 1 |
Pratten, MK | 1 |
De Long, NE | 1 |
Barra, NG | 1 |
Hardy, DB | 1 |
Patnode, CD | 1 |
Henderson, JT | 1 |
Thompson, JH | 1 |
Senger, CA | 1 |
Fortmann, SP | 1 |
Whitlock, EP | 1 |
Siu, AL | 1 |
Leung, LW | 1 |
Davies, GA | 1 |
Blitz, J | 1 |
West, H | 3 |
Clark, SM | 3 |
Hankins, GD | 8 |
Bérard, A | 1 |
Zhao, JP | 1 |
Sheehy, O | 1 |
Xu, M | 1 |
Abdel-Rahman, SZ | 1 |
Gopalakrishnan, K | 1 |
More, AS | 1 |
Kumar, S | 1 |
Feinn, RS | 1 |
Jain, SK | 1 |
Hebert, R | 1 |
Oztuna, F | 1 |
Rore, C | 1 |
Brace, V | 1 |
Danielian, P | 1 |
Williams, D | 1 |
Tschabitscher, P | 1 |
Homaier, I | 1 |
Lichtenschopf, A | 1 |
Groman, E | 1 |
Earhart, AD | 1 |
Patrikeeva, S | 1 |
Abdelrahman, DR | 5 |
Maritz, GS | 1 |
Oncken, CA | 2 |
Hudmon, KS | 1 |
Corelli, RL | 1 |
Prokhorov, AV | 1 |
Zharikova, OL | 1 |
Chisolm, MS | 1 |
Brigham, EP | 1 |
Tuten, M | 1 |
Strain, EC | 1 |
Jones, HE | 1 |
Anderka, M | 1 |
Romitti, PA | 1 |
Sun, L | 1 |
Druschel, C | 1 |
Carmichael, S | 1 |
Shaw, G | 1 |
Alwan, S | 2 |
Botto, LD | 1 |
Rasmussen, SA | 2 |
Correa, A | 1 |
Friedman, JM | 2 |
Leventhal, K | 1 |
Byatt, N | 1 |
Lundquist, R | 1 |
Hemauer, SJ | 1 |
Figueroa, R | 1 |
Agboola, S | 1 |
McNeill, A | 2 |
Leonardi Bee, J | 1 |
Karila, L | 1 |
Reynaud, M | 1 |
Gisslen, T | 1 |
Nathan, B | 1 |
Thompson, T | 1 |
Rao, R | 1 |
Mardle, T | 1 |
Merrett, S | 1 |
Wright, J | 1 |
Percival, F | 1 |
Lockhart, I | 1 |
Schroeder, JW | 1 |
Smith, AK | 1 |
Brennan, PA | 1 |
Conneely, KN | 1 |
Kilaru, V | 1 |
Knight, BT | 1 |
Newport, DJ | 1 |
Cubells, JF | 1 |
Stowe, ZN | 1 |
Larzelere, MM | 1 |
Williams, DE | 1 |
Myung, SK | 1 |
Ju, W | 1 |
Jung, HS | 1 |
Park, CH | 1 |
Oh, SW | 1 |
Seo, H | 1 |
Kim, H | 1 |
Dickmann, LJ | 1 |
Thyagarajan, V | 1 |
Robin Clifford, C | 1 |
Wurst, KE | 1 |
Ephross, SA | 1 |
Seeger, JD | 1 |
Yang, Y | 1 |
Shimomura, K | 1 |
Sakuma, K | 1 |
Maejima, Y | 1 |
Iwasaki, Y | 1 |
Galvanovskis, J | 1 |
Dezaki, K | 1 |
Nakata, M | 1 |
Yada, T | 1 |
Kotlyar, M | 1 |
Hatsukami, DK | 1 |
Baab, SW | 1 |
Peindl, KS | 1 |
Piontek, CM | 1 |
Wisner, KL | 1 |
Boshier, A | 2 |
Wilton, LV | 1 |
Shakir, SA | 1 |
Dell, DL | 1 |
O'Brien, BW | 1 |
Benowitz, N | 1 |
Dempsey, D | 1 |
Chun-Fai-Chan, B | 1 |
Koren, G | 2 |
Fayez, I | 1 |
Kalra, S | 1 |
Voyer-Lavigne, S | 1 |
Shakir, S | 1 |
Einarson, A | 2 |
Chan, B | 1 |
Nonacs, RM | 1 |
Soares, CN | 1 |
Viguera, AC | 1 |
Pearson, K | 1 |
Poitras, JR | 1 |
Cohen, LS | 1 |
Foulds, J | 1 |
Steinberg, MB | 1 |
Williams, JM | 1 |
Ziedonis, DM | 1 |
Hsiao, SY | 1 |
Cherng, CF | 2 |
Yang, YK | 1 |
Yeh, TL | 1 |
Yu, L | 2 |
Cole, JA | 1 |
Modell, JG | 1 |
Haight, BR | 1 |
Cosmatos, IS | 1 |
Stoler, JM | 1 |
Walker, AM | 1 |
Su, SW | 1 |
Lin, YC | 1 |
Rigotti, NA | 1 |
Park, ER | 1 |
Chang, Y | 1 |
Regan, S | 1 |
Crawford, JT | 1 |
Tolosa, JE | 1 |
Goldenberg, RL | 2 |
Tucker, WE | 1 |
Leibenluft, E | 1 |
Okuyemi, KS | 1 |
Ahluwalia, JS | 1 |
Harris, KJ | 1 |
Benowitz, NL | 1 |
Dempsey, DA | 1 |
Hughes, JR | 1 |
Dolan-Mullen, P | 1 |
Ogburn, PL | 1 |
Orleans, CT | 1 |
Slotkin, TA | 1 |
Whiteside, HP | 1 |
Yaffe, S | 1 |
Raw, M | 1 |
Pedersen, ST | 1 |
Christensen, HR | 1 |
Døssing, M | 1 |
Peters, MJ | 1 |
Morgan, LC | 1 |
de Greef, WJ | 1 |
Voogt, JL | 1 |
Visser, TJ | 1 |
Lamberts, SW | 1 |
van der Schoot, P | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women[NCT02188459] | Phase 2 | 129 participants (Actual) | Interventional | 2014-10-30 | Completed | ||
Smoking Cessation Following Text Message Intervention in Pregnant Women[NCT03024606] | 49 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
"A Randomized Open-label, Superiority, Multicenter, Two-arm Intervention Study of the Effect of High-intensity vs. 'Low-intensity' Smoking Cessation Intervention in Active Smokers With COPD"[NCT04088942] | Phase 4 | 0 participants (Actual) | Interventional | 2023-07-01 | Withdrawn (stopped due to No funding) | ||
The Relative Efficacy of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD) Versus Medication Only and the Combination of the Two: A Pilot Study[NCT02788851] | 70 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | |||
Bupropion for Smoking Cessation During Pregnancy[NCT01390246] | Phase 4 | 65 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
Effectiveness of WhatsApp Online Group Discussion for Smoking Relapse Prevention: a Pragmatic Randomized Controlled Trial[NCT03760224] | 928 participants (Actual) | Interventional | 2018-10-04 | Completed | |||
Perinatal Stress and Gene Influences: Pathways to Infant Vulnerability[NCT00525226] | 1,431 participants (Actual) | Observational | 2007-09-30 | Completed | |||
Assessment of the Effectiveness of Nicotine Replacement Therapies (Nicotine Patches Delivering Nicotine 16 h/24 h) in 400 Pregnant Smokers. Randomized, Placebo-controlled, Multicenter, National Study. The SNIPP.[NCT00507975] | Phase 3 | 404 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
A Retrospective, Real-life Evaluation of the Cardiovascular Disease Risk Associated With Exposure to Pharmacological Smoking Cessation Interventions in a Representative UK Primary Care Patient Population.[NCT02195739] | 61,050 participants (Actual) | Observational | 2013-09-30 | Active, not recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Birth outcomes obtained from labor and delivery records 5-minute Appearance, Pulse, Grimace, Activity, and Respiration score (APGAR). The Apgar score has a range from 0 to 10. A 5-minute Apgar score of 7-10 as reassuring, a score of 4-6 as moderately abnormal, and a score of 0-3 as low in the term infant and late-preterm infant 6. (NCT02188459)
Timeframe: postpartum
Intervention | score on a scale (Mean) |
---|---|
Bupropion | 8.9 |
Placebo | 8.6 |
Birth outcomes obtained from labor and delivery records gestational age, measured in weeks. (NCT02188459)
Timeframe: Postpartum
Intervention | weeks (Mean) |
---|---|
Bupropion | 37.1 |
Placebo | 38.1 |
Birth outcomes obtained from labor and delivery records head circumference measured in centimeters. (NCT02188459)
Timeframe: Postpartum
Intervention | cm (Mean) |
---|---|
Bupropion | 33.3 |
Placebo | 33.0 |
Birth outcomes obtained from labor and delivery records infant size for gestational age, whether small for gestational age (i.e., <10th percentile birth weight for gestational age as determined by the Alexander curve). (NCT02188459)
Timeframe: Postpartum
Intervention | percentile (Mean) |
---|---|
Bupropion | 32.0 |
Placebo | 32.5 |
Birth weight outcomes were obtained from labor and delivery clinical records. Birth weight is measure in grams. (NCT02188459)
Timeframe: Postpartum
Intervention | grams (Mean) |
---|---|
Bupropion | 2925.9 |
Placebo | 2996.5 |
For adverse effects, our primary outcome will be the frequency of moderate or severe side effects from a checklist of bupropion-related side effects (derived from completed bupropion studies), as well as those elicited with open-ended questions, through regular obstetrics visits, and assessments triggered by any pregnancy-related complication. Adverse effects will be systematically assessed by study personnel at 5 time points over the course of the 10-week study and can trigger dose reductions or suspension of medication. (NCT02188459)
Timeframe: 10 week treatment phase
Intervention | adverse effects (Mean) |
---|---|
Placebo | .7 |
Bupropion | 1.1 |
Participants will be considered to be abstinent if they self-report abstinence (not even a puff of a cigarette) for >7 days prior to the assessment after 10 weeks of treatment post-To Quit Day and have a CO <8 ppm at that time. As per convention, participants are assumed to be smoking if they self-report to be smoking at the time point, cannot be reached to provide data at the time point, fail to provide a breath sample at the time point, or provide a breath sample at the time point that has a CO concentration >8 ppm. (NCT02188459)
Timeframe: 10 weeks
Intervention | Participants with cessation success (Number) |
---|---|
Placebo Group | 12 |
Bupropion Group | 7 |
self-reported cessation rates at 1 month, as verified by exhaled carbon monoxide levels (NCT03024606)
Timeframe: 1 month
Intervention | Participants (Count of Participants) |
---|---|
Texting Group | 8 |
Control Group | 5 |
The accuracy of self-reported smoking abstinence during study visits was confirmed by an exhaled carbon monoxide (CO) levels and by urinary cotinine levels. 7-day point prevalence abstinence was defined as no cigarettes (not even a puff) in the last 7 days, levels of (CO) in exhaled air < 4 ppm, and concentrations of cotinine in urine < 50 ng/mL. At every visit, a research nurse monitored the smoking status of all subjects (amount of cigarettes per day, exhaled CO). Exhaled CO was measured using a Vitalograph carbon monoxide monitor (Lenexa, KS) according to the manufacturer's recommendations. A urine sample was collected at each visit and cotinine in urine was quantified using the validated liquid chromatography-mass spectrometry (LC/MS) method. We calculated the total number of abstinent subjects. The higher the number the better outcome. (NCT01390246)
Timeframe: Visit 6 (end of 12 weeks of medication therapy)
Intervention | Participants (Count of Participants) |
---|---|
Bupropion SR | 5 |
Placebo | 1 |
The accuracy of self-reported smoking abstinence during study visits was confirmed by an exhaled carbon monoxide (CO) levels and by urinary cotinine levels. 7-day point prevalence abstinence was defined as no cigarettes (not even a puff) in the last 7 days, levels of (CO) in exhaled air < 4 ppm, and concentrations of cotinine in urine < 50 ng/mL. At every visit, a research nurse monitored the smoking status of all subjects (amount of cigarettes per day, exhaled CO). Exhaled CO was measured using a Vitalograph carbon monoxide monitor (Lenexa, KS) according to the manufacturer's recommendations. A urine sample was collected at each visit and cotinine in urine was quantified using the validated liquid chromatography-mass spectrometry (LC/MS) method. We calculated the total number of abstinent subjects. The higher the number the better outcome. (NCT01390246)
Timeframe: End of pregnancy (visit 7) is a time period between 36.0-38.6 weeks gestation
Intervention | Participants (Count of Participants) |
---|---|
Bupropion SR | 3 |
Placebo | 1 |
Cigarette craving and withdrawal symptoms were assessed by the Minnesota Nicotine Withdrawal Scale (MNWS). MNWS consists of 7 objectives (e.g., irritability, anxious, depressed mood, difficulty concentrating, increased appetite, insomnia, restless). Subjects were given a score on each item on a scale of 0 (not present) to 4 (severe). Summed (total) score excluding craving represent subject's symptoms of tobacco withdrawal, ranging from 0 to 28. We calculated a craving for tobacco score and a total score of withdrawal symptoms excluding craving. The higher score represent more sever craving and withdrawal. (NCT01390246)
Timeframe: During treatment: Visits 2-6 (time period between 2nd and 12th week of therapy)
Intervention | MNWS Score (Mean) | |
---|---|---|
Craving for tobacco | Total score of withdrawal excluding craving | |
Bupropion SR | 1.50 | 3.77 |
Placebo | 2.07 | 5.35 |
Cigarette craving and withdrawal symptoms were assessed by the Minnesota Nicotine Withdrawal Scale (MNWS). MNWS consists of 7 objectives (e.g., irritability, anxious, depressed mood, difficulty concentrating, increased appetite, insomnia, restless). Subjects were given a score on each item on a scale of 0 (not present) to 4 (severe). Summed (total) score excluding craving represent subject's symptoms of tobacco withdrawal, ranging from 0 to 28. We calculated a craving for tobacco score and a total score of withdrawal symptoms excluding craving. The higher score represent more sever craving and withdrawal. (NCT01390246)
Timeframe: Quit date, visit 2 (one week after starting the 12-week course of therapy)
Intervention | MNWS Score (Mean) | |
---|---|---|
Craving for tobacco | Total score of withdrawal excluding craving | |
Bupropion SR | 2.04 | 4.75 |
Placebo | 2.33 | 4.88 |
Quality of Life Inventory (QoLI) , 7 items with 3-point rating scale for importance (1 not important, 3 very important), and 3-point rating scale for satisfaction (1 not satisfied, 3 very satisfied) in terms of health, economy, work, hobbies, relationship with partner, friendship and relationship with family. (NCT03760224)
Timeframe: 12 month
Intervention | scores on a scale (Mean) |
---|---|
Intervention | 2.50 |
Control | 2.46 |
Quality of Life Inventory (QoLI) , 7 items with 3-point rating scale for importance (1 not important, 3 very important), and 3-point rating scale for satisfaction (1 not satisfied, 3 very satisfied) in terms of health, economy, work, hobbies, relationship with partner, friendship and relationship with family. (NCT03760224)
Timeframe: 6 month
Intervention | score on a scale (Mean) |
---|---|
Intervention | 2.45 |
Control | 2.31 |
EuroQol 5-dimension 5 level (EQ-5D-5L) health utility scores on a 1 (No problem) -5 (unable or extreme pain/ anxious) scales which assess participants mobility, self care, usual activities, pain/ discomfort and their anxiety/ depression. After obtaining the data, results were re-calculated and transferred based on Hong Kong population norm. After calculation, the total score ranged from -0.864 to 1. Higher score indicates better health status. Calculations of this scale were based on Hong Kong population provided by Wong EL and colleagues (Wong EL, Ramos-Goni JM, Cheung AW, Wong AY, Rivero-Arias O. Assessing the use of a feedback module to model EQ-5D-5L health states values in Hong Kong. The Patient-Patient-Centered Outcomes Research. 2018 Apr;11(2):235-47.). (NCT03760224)
Timeframe: 12 month
Intervention | score on a scale (Mean) |
---|---|
Intervention | 0.97 |
Control | 0.97 |
EuroQol 5-dimension 5 level (EQ-5D-5L) health utility scores on a 1 (No problem) -5 (unable or extreme pain/ anxious) scales which assess participants mobility, self care, usual activities, pain/ discomfort and their anxiety/ depression. After obtaining the data, results were re-calculated and transferred based on Hong Kong population norm. After calculation, the total score ranged from -0.864 to 1. Higher score indicates better health status. Calculations of this scale were based on Hong Kong population provided by Wong EL and colleagues (Wong EL, Ramos-Goni JM, Cheung AW, Wong AY, Rivero-Arias O. Assessing the use of a feedback module to model EQ-5D-5L health states values in Hong Kong. The Patient-Patient-Centered Outcomes Research. 2018 Apr;11(2):235-47.). (NCT03760224)
Timeframe: 3 month
Intervention | score on a scale (Mean) |
---|---|
Intervention | 0.96 |
Control | 0.97 |
EuroQol 5-dimension 5 level (EQ-5D-5L) health utility scores on a 1 (No problem) -5 (unable or extreme pain/ anxious) scales which assess participants mobility, self care, usual activities, pain/ discomfort and their anxiety/ depression. After obtaining the data, results were re-calculated and transferred based on Hong Kong population norm. After calculation, the total score ranged from -0.864 to 1. Higher score indicates better health status. Calculations of this scale were based on Hong Kong population provided by Wong EL and colleagues (Wong EL, Ramos-Goni JM, Cheung AW, Wong AY, Rivero-Arias O. Assessing the use of a feedback module to model EQ-5D-5L health states values in Hong Kong. The Patient-Patient-Centered Outcomes Research. 2018 Apr;11(2):235-47.). (NCT03760224)
Timeframe: 6 month
Intervention | score on a scale (Mean) |
---|---|
Intervention | 0.96 |
Control | 0.95 |
Frequency (in the past week) of smoking urge will be evaluated according to their frequency of their smoking urges on a scale of 0 (none at all) to 4 (ever hour or more). (NCT03760224)
Timeframe: 12 month
Intervention | score on a scale (Mean) |
---|---|
Intervention | 2.04 |
Control | 2.07 |
Frequency (in the past week) of smoking urge will be evaluated according to their frequency of their smoking urges on a scale of 0 (none at all) to 4 (ever hour or more). (NCT03760224)
Timeframe: 3 month
Intervention | score on a scale (Mean) |
---|---|
Intervention | 2.09 |
Control | 2.13 |
Frequency (in the past week) of smoking urge will be evaluated according to their frequency of their smoking urges on a scale of 0 (none at all) to 4 (ever hour or more). (NCT03760224)
Timeframe: 6 month
Intervention | score on a scale (Mean) |
---|---|
Intervention | 1.72 |
Control | 1.73 |
Intensity (in the past day) of smoking urge will be evaluated according to their intensity of their smoking urges on a scale of 1 (never have smoking urges) to 5 (smoking urges every hour or more). (NCT03760224)
Timeframe: 12 month
Intervention | score on a scale (Mean) |
---|---|
Intervention | 1.37 |
Control | 1.39 |
Intensity (in the past day) of smoking urge will be evaluated according to their intensity of their smoking urges on a scale of 1 (never have smoking urges) to 5 (smoking urges every hour or more). (NCT03760224)
Timeframe: 3 month
Intervention | score on a scale (Mean) |
---|---|
Intervention | 1.70 |
Control | 1.79 |
Intensity (in the past day) of smoking urge will be evaluated according to their intensity of their smoking urges on a scale of 1 (never have smoking urges) to 5 (smoking urges every hour or more). (NCT03760224)
Timeframe: 6 month
Intervention | score on a scale (Mean) |
---|---|
Intervention | 1.46 |
Control | 1.46 |
Minnesota Nicotine Withdrawal Scale (MNWS) using Likert-type scale for the severity ratings, ranging from 0 (not at all) to 4 (severe) in terms of their desire and craving to smoke, insomnia, awakening at night, difficulty in concentration, anxious,depressed, restless and irritable. As the 9 items were rated from 0-4, therefore, the total score ranged from 0-36. A higher score indicates participants had more withdrawal symptoms. (NCT03760224)
Timeframe: 12 month
Intervention | scores on a scale (Mean) |
---|---|
Intervention | 10.90 |
Control | 11.46 |
Minnesota Nicotine Withdrawal Scale (MNWS) using Likert-type scale for the severity ratings, ranging from 0 (not at all) to 4 (severe) in terms of their desire and craving to smoke, insomnia, awakening at night, difficulty in concentration, anxious,depressed, restless and irritable. As the 9 items were rated from 0-4, therefore, the total score ranged from 0-36. A higher score indicates participants had more withdrawal symptoms. (NCT03760224)
Timeframe: 3 month
Intervention | scores on a scale (Mean) |
---|---|
Intervention | 11.85 |
Control | 12.37 |
Minnesota Nicotine Withdrawal Scale (MNWS) using Likert-type scale for the severity ratings, ranging from 0 (not at all) to 4 (severe) in terms of their desire and craving to smoke, insomnia, awakening at night, difficulty in concentration, anxious,depressed, restless and irritable. As the 9 items were rated from 0-4, therefore, the total score ranged from 0-36. A higher score indicates participants had more withdrawal symptoms. (NCT03760224)
Timeframe: 6 month
Intervention | scores on a scale (Mean) |
---|---|
Intervention | 11.30 |
Control | 11.71 |
Self-reported abstinence in the past 7 days at 12-month follow-up (NCT03760224)
Timeframe: 12 month
Intervention | Participants (Count of Participants) |
---|---|
Intervention | 200 |
Control | 216 |
Self-reported abstinence in the past 7 days at 6-month follow-up (NCT03760224)
Timeframe: 6 month
Intervention | Participants (Count of Participants) |
---|---|
Intervention | 229 |
Control | 232 |
Exhaled carbon monoxide below 4ppm using a Smokerlyzer, and a saliva cotinine 10ng/ml or below using the iScreen OFD Cotinine Saliva Test Kit (NCT03760224)
Timeframe: 12 month
Intervention | Participants (Count of Participants) |
---|---|
Intervention | 56 |
Control | 54 |
Exhaled carbon monoxide below 4ppm using a Smokerlyzer, and a saliva cotinine 10ng/ml or below using the iScreen OFD Cotinine Saliva Test Kit (NCT03760224)
Timeframe: 6 month
Intervention | Participants (Count of Participants) |
---|---|
Intervention | 69 |
Control | 75 |
Self-reported continuous abstinence (NCT03760224)
Timeframe: 3 month
Intervention | Participants (Count of Participants) |
---|---|
Intervention | 256 |
Control | 257 |
Consuming 5 cigarettes or more in 3 consecutive days in the past 12 months (NCT03760224)
Timeframe: 12 month
Intervention | Participants (Count of Participants) |
---|---|
Intervention | 269 |
Control | 243 |
Consuming 5 cigarettes or more in 3 consecutive days in the past 3 months (NCT03760224)
Timeframe: 3 month
Intervention | Participants (Count of Participants) |
---|---|
Intervention | 213 |
Control | 202 |
Consuming 5 cigarettes or more in 3 consecutive days in the past 6 months (NCT03760224)
Timeframe: 6 month
Intervention | Participants (Count of Participants) |
---|---|
Intervention | 240 |
Control | 227 |
Self-reported abstinence in the past 7 days at 3-month follow-up (NCT03760224)
Timeframe: 3 month
Intervention | Participants (Count of Participants) |
---|---|
Intervention | 256 |
Control | 257 |
Self-reported continuous abstinence (NCT03760224)
Timeframe: 12 month
Intervention | Participants (Count of Participants) |
---|---|
Intervention | 130 |
Control | 141 |
Self-reported continuous abstinence (NCT03760224)
Timeframe: 6 month
Intervention | Participants (Count of Participants) |
---|---|
Intervention | 185 |
Control | 187 |
35 reviews available for bupropion and Pregnancy
Article | Year |
---|---|
Clinical Practice Guideline of Spanish Society of Pneumology and Thoracic Surgery (SEPAR) on Pharmacological Treatment of Tobacco Dependence 2023.
Topics: Adolescent; Alcoholism; Bupropion; Female; Humans; Nicotinic Agonists; Pregnancy; Pulmonary Medicine | 2023 |
Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses.
Topics: Adult; Bupropion; Electronic Nicotine Delivery Systems; Female; Humans; Network Meta-Analysis; Nicot | 2023 |
Pharmacological interventions for promoting smoking cessation during pregnancy.
Topics: Bupropion; Female; Humans; Nicotinic Agonists; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 2020 |
Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons.
Topics: Adult; Anxiety Disorders; Bupropion; Counseling; Female; Humans; Pregnancy; Pregnancy Complications; | 2021 |
Tobacco Harms, Nicotine Pharmacology, and Pharmacologic Tobacco Cessation Interventions for Women.
Topics: Bupropion; Female; Fetus; Humans; Lactation; Nicotiana; Nicotine; Pregnancy; Pregnant Women; Smoking | 2017 |
Bupropion Use During Pregnancy: A Systematic Review.
Topics: Abortion, Spontaneous; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Pregnancy; Pregnancy C | 2017 |
Pharmacotherapy for Perinatal Depression.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Antidepressive Agents, Tricyclic; Autism Spectru | 2018 |
Systematic Review and Meta-Analysis to Assess the Safety of Bupropion and Varenicline in Pregnancy.
Topics: Bupropion; Case-Control Studies; Female; Humans; Nicotinic Agonists; Pregnancy; Pregnancy Complicati | 2019 |
Pharmaceutical strategies for smoking cessation during pregnancy.
Topics: Bupropion; Female; Humans; Pregnancy; Pregnancy Complications; Smoking; Smoking Cessation; Tobacco U | 2018 |
Relapse prevention interventions for smoking cessation.
Topics: Behavior Therapy; Bupropion; Chewing Gum; Female; Humans; Male; Nicotine; Nicotinic Agonists; Pregna | 2019 |
Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation.
Topics: Behavior Therapy; Bupropion; Combined Modality Therapy; Female; Humans; Nicotinic Agonists; Nortript | 2019 |
Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice.
Topics: Adolescent; Benzazepines; Bupropion; Counseling; Drug Design; Female; Humans; Molecular Sequence Dat | 2014 |
Cochrane review summary: Pharmacological interventions for promoting smoking cessation during pregnancy.
Topics: Antidepressive Agents, Second-Generation; Benzazepines; Birth Weight; Bupropion; Female; Humans; Inf | 2013 |
Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews.
Topics: Antidepressive Agents, Second-Generation; Behavior Therapy; Benzazepines; Bupropion; Counseling; Fem | 2014 |
Is it safe to use smoking cessation therapeutics during pregnancy?
Topics: Animals; Benzazepines; Bupropion; Female; Humans; Pregnancy; Quinoxalines; Smoking; Smoking Cessatio | 2014 |
Behavioral Counseling and Pharmacotherapy Interventions for Tobacco Cessation in Adults, Including Pregnant Women: A Review of Reviews for the U.S. Preventive Services Task Force.
Topics: Adult; Behavior Therapy; Bupropion; Counseling; Electronic Nicotine Delivery Systems; Female; Humans | 2015 |
Smoking Cessation Strategies in Pregnancy.
Topics: Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Nicotinic Agonists; Pregnancy; Smoking Cessat | 2015 |
Pharmacological interventions for promoting smoking cessation during pregnancy.
Topics: Bupropion; Female; Humans; Nicotinic Agonists; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 2015 |
[Treatment of smoking cessation during pregnancy].
Topics: Adult; Antidepressive Agents, Second-Generation; Behavior Therapy; Bupropion; Chewing Gum; Combined | 2008 |
Smoking cessation in pregnancy.
Topics: Animals; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Nicotine; Nicotinic Ag | 2008 |
Are nicotine replacement therapy, varenicline or bupropion options for pregnant mothers to quit smoking? Effects on the respiratory system of the offspring.
Topics: Animals; Antioxidants; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Maternal | 2009 |
What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?
Topics: Animals; Benzazepines; Bupropion; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fem | 2009 |
Current approaches to pharmacotherapy for smoking cessation.
Topics: Adolescent; Adult; Animals; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Mal | 2010 |
A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers.
Topics: Bupropion; Counseling; Dopamine Uptake Inhibitors; Female; Humans; Nicotinic Agonists; Patient Educa | 2010 |
Pharmacotherapy for smoking cessation: present and future.
Topics: Adolescent; Animals; Benzazepines; Bupropion; Delayed-Action Preparations; Female; Humans; Nicotine; | 2011 |
Efficacy and safety of pharmacotherapy for smoking cessation among pregnant smokers: a meta-analysis.
Topics: Adult; Benzazepines; Bupropion; Controlled Clinical Trials as Topic; Dopamine Uptake Inhibitors; Epi | 2012 |
Managing nicotine addiction.
Topics: Administration, Inhalation; Adolescent; Adult; Antidepressive Agents, Tricyclic; Bupropion; Chewing | 2002 |
Pharmacotherapies to enhance smoking cessation during pregnancy.
Topics: Administration, Cutaneous; Administration, Inhalation; Administration, Intranasal; Antidepressive Ag | 2003 |
Pharmacotherapy for smoking cessation during pregnancy.
Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Female; Ganglionic Stimulants; Humans; Nicotine; Pregn | 2004 |
Developments in pharmacotherapy for tobacco dependence: past, present and future.
Topics: Adolescent; Adult; Bupropion; Clinical Trials as Topic; Clonidine; Drug Administration Routes; Femal | 2006 |
Smoking cessation in pregnancy: why, how, and what next...
Topics: Behavior Therapy; Benzazepines; Bupropion; Counseling; Female; Humans; Nicotine; Pregnancy; Pregnanc | 2008 |
Issues in the treatment of women with bipolar illness.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bipolar Disorder; Buprop | 1997 |
Pharmacotherapy of smoking cessation.
Topics: Administration, Cutaneous; Administration, Inhalation; Antidepressive Agents, Second-Generation; Bup | 2000 |
[Treatment of nicotine addiction. Drug therapy for smoking cessation].
Topics: Administration, Inhalation; Administration, Intranasal; Antidepressive Agents, Second-Generation; Bu | 2002 |
The pharmacotherapy of smoking cessation.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Chewing Gum; Contraindications; Female; Humans; | 2002 |
8 trials available for bupropion and Pregnancy
Article | Year |
---|---|
A gender-based secondary analysis of the ADAPT-2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial.
Topics: Adult; Bupropion; Central Nervous System Stimulants; Double-Blind Method; Drug Therapy, Combination; | 2023 |
Placebo-controlled trial of bupropion for smoking cessation in pregnant women.
Topics: Bupropion; Female; Humans; Infant; Infant, Newborn; Pregnancy; Pregnancy Outcome; Pregnant Women; Sm | 2021 |
Smoking Cessation Following Text Message Intervention in Pregnant Women.
Topics: Adult; Bupropion; Female; Follow-Up Studies; Humans; Maternal Health; Motivation; Pregnancy; Prenata | 2018 |
Randomized, controlled pilot trial of bupropion for pregnant smokers: challenges and future directions.
Topics: Adult; Bayes Theorem; Bupropion; Double-Blind Method; Female; Humans; Pilot Projects; Poverty; Pregn | 2015 |
Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Breath Tests; Bupropion; Carbon Dioxide; Cotinine; | 2017 |
The relationship between antidepressant use and smoking cessation in pregnant women in treatment for substance abuse.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depressive Disorder, Major; | 2010 |
Bupropion SR for the treatment of postpartum depression: a pilot study.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Bupropion; Depression, Postpartum; Diag | 2005 |
Smoking cessation medication use among pregnant and postpartum smokers.
Topics: Adult; Bupropion; Counseling; Educational Status; Female; Health Care Costs; Humans; Marital Status; | 2008 |
64 other studies available for bupropion and Pregnancy
Article | Year |
---|---|
Comparing newborn outcomes after prenatal exposure to individual antidepressants: A retrospective cohort study.
Topics: Antidepressive Agents; Bupropion; Citalopram; Duloxetine Hydrochloride; Escitalopram; Female; Fluoxe | 2021 |
Environmental enrichment affects behavioral and pharmacological response to antidepressants in CF1 mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Bupropion; Fema | 2023 |
Health-care providers' concern regarding smoking cessation pharmacotherapies during pregnancy: Calls to a teratology information service.
Topics: Australia; Behavior Therapy; Bupropion; Call Centers; Female; Health Personnel; Humans; Information | 2020 |
Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study.
Topics: Analgesics, Opioid; Bupropion; Cotinine; Female; Humans; Methadone; Nicotine; Opiate Substitution Tr | 2020 |
Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Bupropion; Case-Control Studies; Child; Female; Huma | 2020 |
Development and Validation of a Model to Predict Neonatal Abstinence Syndrome.
Topics: Adult; Analgesics; Antiemetics; Antipsychotic Agents; Benzodiazepines; Bupropion; Female; Gabapentin | 2021 |
Why the Maternal Medication List Matters: Neonatal Toxicity From Combined Serotonergic Exposures.
Topics: Antidepressive Agents; Bipolar Disorder; Brain Diseases; Bupropion; Drug Therapy, Combination; Dyski | 2021 |
Pregnancy Has No Clinically Significant Effect on the Pharmacokinetics of Bupropion or Its Metabolites.
Topics: Antidepressive Agents; Bupropion; Female; Humans; Placenta; Postpartum Period; Pregnancy | 2021 |
Medicaid Coverage of Smoking Cessation Counseling and Medication Is Underutilized for Pregnant Women.
Topics: Adult; Bupropion; Counseling; Databases, Factual; Dopamine Uptake Inhibitors; Female; Humans; Insura | 2017 |
The Role of Placental Carbonyl Reducing Enzymes in Biotransformation of Bupropion and 4-methylnitrosamino-1-(3-pyridyl)-1-butanone.
Topics: Antidepressive Agents; Biotransformation; Bupropion; Cigarette Smoking; Female; Humans; Microsomes; | 2017 |
Paternal exposure to bupropion affects postnatal development in the offspring.
Topics: Animals; Animals, Newborn; Behavior, Animal; Bupropion; Female; Growth and Development; Male; Mice; | 2019 |
Postnatal metabolic and reproductive consequences of fetal and neonatal exposure to the smoking cessation drug bupropion.
Topics: Animals; Animals, Newborn; Bupropion; Female; Male; Pregnancy; Prenatal Exposure Delayed Effects; Ra | 2013 |
First-trimester exposure to bupropion and risk of cardiac malformations.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antidepressive Agents, Second-Generation; Bupropion; | 2014 |
ADHD and pregnancy.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; | 2014 |
Metabolism and disposition of bupropion in pregnant baboons (Papio cynocephalus).
Topics: Animals; Biotransformation; Bupropion; Female; Papio cynocephalus; Postpartum Period; Pregnancy; Pre | 2014 |
Evaluation of bupropion hydrochloride developmental cardiotoxic effects in chick cardiomyocyte micromass culture and stem cell derived cardiomyocyte systems.
Topics: Animals; Antidepressive Agents, Second-Generation; Bupropion; Cardiotoxins; Cell Differentiation; Ce | 2014 |
Behavioral and Pharmacotherapy Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Women: U.S. Preventive Services Task Force Recommendation Statement.
Topics: Adult; Behavior Therapy; Biomedical Research; Bupropion; Cost of Illness; Counseling; Electronic Nic | 2015 |
Summaries for Patients. Behavioral and Pharmacologic Treatments to Help Adults Quit Smoking: U.S. Preventive Services Task Force Recommendation Statement.
Topics: Adult; Behavior Therapy; Bupropion; Counseling; Electronic Nicotine Delivery Systems; Female; Humans | 2015 |
Drugs for smoking cessation.
Topics: Bupropion; Contraindications; Dopamine Uptake Inhibitors; Drug Monitoring; Female; Humans; Middle Ag | 2016 |
Behavioral and Pharmacotherapy Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Women.
Topics: Adult; Behavior Therapy; Bupropion; Counseling; Female; Humans; Pregnancy; Pregnancy Complications; | 2016 |
Behavioral and Pharmacotherapy Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Women: Recommendation Statement.
Topics: Adult; Behavior Therapy; Bupropion; Combined Modality Therapy; Counseling; Electronic Nicotine Deliv | 2016 |
Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid.
Topics: Adult; Amniotic Fluid; Antidepressive Agents, Second-Generation; Bupropion; Depression; Female; Feta | 2016 |
Success of smoking cessation interventions during pregnancy.
Topics: Adolescent; Adult; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Infant, Newborn; Infant, P | 2016 |
Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy.
Topics: Adult; Alleles; Antidepressive Agents, Second-Generation; Bupropion; Cytochrome P-450 CYP2B6; Cytoch | 2016 |
Postnatal Cardiovascular Consequences in the Offspring of Pregnant Rats Exposed to Smoking and Smoking Cessation Pharmacotherapies.
Topics: Animals; Bupropion; Female; Heart; Myocytes, Cardiac; Pregnancy; Prenatal Exposure Delayed Effects; | 2017 |
What's new in nicotine & tobacco research?
Topics: Adolescent; Adolescent Behavior; Adult; Bupropion; Female; Humans; Male; Pregnancy; Pregnancy Compli | 2008 |
Prescribing during pregnancy. Prenatal drug exposure and an untreated psychiatric disorder both present risks.
Topics: Antidepressive Agents, Tricyclic; Antimanic Agents; Bupropion; Depressive Disorder; Dopamine Uptake | 2008 |
[Varenicline - pharmacological therapy of tobacco dependence].
Topics: Adolescent; Adult; Aged; Benzazepines; Bupropion; Clinical Trials as Topic; Contraindications; Doubl | 2009 |
Transplacental transfer and metabolism of bupropion.
Topics: Bupropion; Cell Survival; Chorionic Gonadotropin; Dopamine Uptake Inhibitors; Female; Humans; Matern | 2010 |
Bupropion metabolism by human placenta.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hy | 2010 |
Patterns of tobacco exposure before and during pregnancy.
Topics: Adult; Bupropion; Cohort Studies; Dopamine Uptake Inhibitors; Female; Fertilization; Humans; Infant, | 2010 |
Maternal use of bupropion and risk for congenital heart defects.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Case-Control Studies; Chi-Square Distrib | 2010 |
Fetal cardiac arrhythmia during bupropion use.
Topics: Adult; Antidepressive Agents, Second-Generation; Arrhythmias, Cardiac; Atrial Premature Complexes; B | 2010 |
Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion.
Topics: Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport | 2010 |
Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring.
Topics: Adult; Antidepressive Agents, Second-Generation; Attention Deficit Disorder with Hyperactivity; Bipo | 2010 |
Patterns of antidepressant medication use among pregnant women in a United States population.
Topics: Antidepressive Agents; Bupropion; Case-Control Studies; Female; Humans; Pregnancy; Pregnancy Complic | 2011 |
State medicaid coverage for tobacco-dependence treatments --- United States, 2009.
Topics: Bupropion; Dopamine Uptake Inhibitors; Eligibility Determination; Fee-for-Service Plans; Female; Gan | 2010 |
Metabolism of bupropion by baboon hepatic and placental microsomes.
Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Female; Liver; Microsomes; Molecular Structure; Papi | 2011 |
Hyperinsulinism associated with gestational exposure to bupropion in a newborn infant.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Female; Humans; Hyperinsulinism; Hypoglycemia; | 2011 |
Real world evaluation of three models of NHS smoking cessation service in England.
Topics: Adolescent; Adult; Benzazepines; Bupropion; Community Health Services; Counseling; England; Female; | 2012 |
DNA methylation in neonates born to women receiving psychiatric care.
Topics: Antidepressive Agents; Antiemetics; Bupropion; CpG Islands; Depressive Disorder, Major; DNA Methylat | 2012 |
Bupropion: congenital heart defects (continued).
Topics: Bupropion; Dopamine Uptake Inhibitors; Drug Monitoring; Female; Heart Defects, Congenital; Humans; I | 2012 |
Promoting smoking cessation.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Complementary | 2012 |
Simultaneous quantitative determination of bupropion and its three major metabolites in human umbilical cord plasma and placental tissue using high-performance liquid chromatography-tandem mass spectrometry.
Topics: Acetonitriles; Biotransformation; Buffers; Bupropion; Calibration; Chemical Precipitation; Chromatog | 2012 |
Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy.
Topics: Analgesics, Opioid; Aryl Hydrocarbon Hydroxylases; Biotransformation; Bupropion; Carbamazepine; Cell | 2013 |
Bupropion therapy in pregnancy and the occurrence of cardiovascular malformations in infants.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Bupropion; Cardiovascular Abnormalities | 2012 |
Bupropion can close KATP channel and induce insulin secretion.
Topics: Animals; Antidepressive Agents, Second-Generation; Bupropion; Female; Humans; Hyperinsulinism; Infan | 2013 |
Serum bupropion levels in 2 breastfeeding mother-infant pairs.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Breast Feeding; Bupropion; Depres | 2002 |
Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Bupropion; Coho | 2003 |
Suicide in pregnancy.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Female; Humans; Pregna | 2003 |
[Recommendation of good practice: Therapeutic strategies, with or without the assistance of medicine-based treatment, for stopping smoking (May 2003)].
Topics: Adolescent; Alcohol Drinking; Bupropion; Cotinine; Female; Humans; MEDLINE; Nicotine; Pregnancy; Smo | 2004 |
Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Antidepressive Agents, Second-Generation; Birth | 2005 |
Effectiveness of bupropion for smoking cessation during pregnancy.
Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Pregnancy; Pregnancy Complications; Se | 2005 |
Bupropion (amfebutamone): caution during pregnancy.
Topics: Amphetamines; Antidepressive Agents, Second-Generation; Bupropion; Congenital Abnormalities; Contrai | 2005 |
Prenatal bupropion exposure enhances the cocaine reward and stress susceptibility in adult mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Citalopram; Cocaine; Conditio | 2005 |
Bupropion in pregnancy and the prevalence of congenital malformations.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Bupropion; Congenital Abnormalities; Da | 2007 |
Prenatal exposure of bupropion may enhance agitation, anxiety responses, and sensitivity to cocaine effects in adult mice.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Cocaine; Dose-Response | 2007 |
Psychopharmacology news. New side effects of agents.
Topics: Benzodiazepines; Bupropion; Female; Humans; Olanzapine; Pregnancy; Propranolol; Psychotropic Drugs; | 2007 |
Stat bite: Medicaid coverage of tobacco-dependence treatments.
Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Antidepressive Agents, | 2008 |
Preclinical toxicology of bupropion: an overview.
Topics: Abnormalities, Drug-Induced; Animals; Antidepressive Agents; Bupropion; Central Nervous System; Chem | 1983 |
The use of pharmacotherapies for smoking cessation during pregnancy.
Topics: Antidepressive Agents; Bupropion; Education; Female; Health Promotion; Humans; Nortriptyline; Pregna | 2000 |
Smoking cessation guidelines for health professionals: an update. Health Education Authority.
Topics: Behavior Therapy; Bupropion; Evidence-Based Medicine; Family Practice; Female; Humans; National Heal | 2000 |
Cutaneous drug reaction case reports: from the world literature.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Bupropion; Celecoxib; Chlorquinaldol; Cytarabi | 2002 |
Control of prolactin release induced by suckling.
Topics: Animals; Bupropion; Dopamine; Female; Hypothalamus; Immunization, Passive; Lactation; Methysergide; | 1987 |